bioRxivMicrobiologyPreprint
Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
P. Qu, J. N. Faraone, J. P. Evans, Y.-M. Zheng, C. Carlin, M. Anghelina, P. Stevens, S. Fernandez, D. Jones, G. Lozanski, A. Panchal, L. J. Saif, E. M. Oltz, K. Xu, R. J. Gumina, S.-L. Liu
Abstract
Newly emerging Omicron subvariants continue to emerge around the world, presenting potential challenges to current vaccination strategies. This study investigates the extent of neutralizing antibody escape by new subvariants XBB.1.5, CH.1.1, and CA.3.1, as well as their impacts on spike protein biology. Our results demonstrated a nearly complete escape of these variants from neutralizing antibodies stimulated by three doses of mRNA vaccine, but neutralization was rescued by a bivalent booster. However, CH.1.1 and CA.3.1 variants were highly resistant to both monovalent and bivalent mRNA vaccinations. We also assessed neutralization by sera from individuals infected during the BA.4/5 wave of infection and observed similar trends of immune escape. In these cohorts, XBB.1.5 did not exhibit enhanced neutralization resistance over the recently dominant BQ.1.1 variant. Notably, the spike proteins of XBB.1.5, CH.1.1, and CA.3.1 all exhibited increased fusogenicity compared to BA.2, correlating with enhanced S processing. Overall, our results support the administration of new bivalent mRNA vaccines, especially in fighting against newly emerged Omicron subvariants, as well as the need for continued surveillance of Omicron subvariants.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immune Evasion and Membrane Fusion of SARS-CoV-2 XBB Subvariants EG.5.1 and XBB.2.3
J. N. Faraone, P. Qu, … S.-L. Liu·bioRxiv·Aug 30, 2023
- Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
N. Lasrado, A.-r. Collier, … D. H. Barouch·bioRxiv·Jan 22, 2023
- XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants
- Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1
- Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
Q. Wang, S. Iketani, … D. D. Ho·bioRxiv·Nov 23, 2022
- Substantial Neutralization Escape by the SARS-CoV-2 Omicron Variant BQ.1.1
J. Miller, N. Hachmann, … D. H. Barouch·bioRxiv·Nov 1, 2022